STALICLA

 https://stalicla.com/

Background

STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs.

The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its first pipeline candidate, STP1, currently in clinical trials. STALICLA is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity to bring 2 phase 2 pipelines in the clinic in 2024. STALICLA achieved a significant milestone by successfully concluding the initial phase of its Series B financing round in January 2024. The company secured an impressive $17.4 million during this first closing. With this recent funding success, STALICLA’s total raised capital now stands at $44.8 million.